durvalumab
Showing 51 - 75 of 367
ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a
Recruiting
- ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
- a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
- Durvalumab
- +2 more
-
Montpellier, France
- +1 more
Nov 16, 2022
EvaluatioN of durvALumab Utilization and Effectiveness for First
Recruiting
- Small Cell Lung Carcinoma
- durvalumab
-
Angers, France
- +24 more
Jan 12, 2023
Non-small-cell Lung Cancer Patients Trial in Roma (Durvalumab, Olaparib tablet, Single-agent chemo)
Recruiting
- Non-small-cell Lung Cancer Patients
- Durvalumab
- +3 more
-
Roma, RM, ItalyIstituti Fisioterapici Ospitalieri- Ifo - Istituto Regina Elena
Sep 30, 2022
Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Extensive Stage Lung Small
Recruiting
- Platinum-Resistant Lung Small Cell Carcinoma
- +3 more
- Durvalumab
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 5, 2023
Lung Cancer, NSCLC, PD-L1 Gene Mutation Trial in Detroit (Durvalumab, Carboplatin, Pemetrexed)
Withdrawn
- Lung Cancer
- +3 more
- Durvalumab
- +2 more
-
Detroit, MichiganHenry Ford Health System
Feb 15, 2022
Oropharyngeal Squamous Cell Carcinoma Trial in Worldwide (Radiation, Cisplatin, Durvalumab)
Recruiting
- Oropharyngeal Squamous Cell Carcinoma
- Radiation
- +3 more
-
Brussels, Belgium
- +25 more
Aug 8, 2022
Intrahepatic Cholangiocarcinoma Trial (procedure, drug, biological)
Not yet recruiting
- Intrahepatic Cholangiocarcinoma
- Biopsy
- +7 more
- (no location specified)
Sep 21, 2023
Gastric Adenocarcinoma, Malignant Melanoma Trial in Seoul (AZD6738, Durvalumab)
Active, not recruiting
- Gastric Adenocarcinoma
- Malignant Melanoma
- AZD6738
- Durvalumab
-
Seoul, Korea, Republic ofSamsung Medical Center
Jun 13, 2022
Malignant Tumors of Digestive Organs, Colorectal Cancer, Colon Cancer Trial in Houston (Durvalumab, Trametinib)
Completed
- Malignant Neoplasms of Digestive Organs
- +2 more
- Durvalumab
- Trametinib
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
May 23, 2022
Non Small Cell Lung Cancer Trial in Lexington (Durvalumab, Copanlisib)
Recruiting
- Non Small Cell Lung Cancer
- Durvalumab
- Copanlisib
-
Lexington, KentuckyMarkey Cancer Center
Feb 21, 2022
Patients With Advanced Treatment Naive LCNEC Trial in Tel Aviv (Durvalumab)
Recruiting
- Patients With Advanced Treatment Naive LCNEC
- Durvalumab
-
Tel Aviv, IsraelAssuta MC
Feb 20, 2022
Carcinoma, Non-Small Cell Lung Trial in Washington, Baltimore (Durvalumab)
Recruiting
- Carcinoma, Non-Small Cell Lung
- Durvalumab
-
Washington, District of Columbia
- +2 more
Jun 10, 2022
Brain Metastases From NSCLC Trial (Stereotactic Radiation Therapy, Durvalumab)
Not yet recruiting
- Brain Metastases From Non-small Cell Lung Cancer
- Stereotactic Radiation Therapy
- Durvalumab
- (no location specified)
May 24, 2022
Larynx, Lip, Oral Cancer Trial in Chapel Hill, Charleston (Durvalumab, Intensity Modulated Radiotherapy Treatments)
Active, not recruiting
- Larynx
- +3 more
- Durvalumab
- Intensity Modulated Radiotherapy Treatments
-
Chapel Hill, North Carolina
- +1 more
May 26, 2022
NSCLC NSCLC Trial in Pittsburgh, Dallas (durvalumab)
Completed
- Non-Small Cell Lung Cancer NSCLC
- durvalumab
-
Pittsburgh, Pennsylvania
- +1 more
Aug 2, 2022
Hepatocellular Carcinoma Trial in Guangzhou (Hepatic artery infusion chemo(HAIC), Durvalumab)
Recruiting
- Hepatocellular Carcinoma
- Hepatic artery infusion chemotherapy（HAIC）
- Durvalumab
-
Guangzhou, Guangdong, ChinaDepartment of Minimally Invasive and Interventional Radiology, L
May 18, 2022
Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma Trial in United States (Durvalumab, Tremelimumab)
Completed
- Endometrial Cancer
- +4 more
- Durvalumab
- Tremelimumab
-
Basking Ridge, New Jersey
- +6 more
Jan 3, 2023
Breast Cancer, Hormone Receptor Positive Tumor Trial in Tampa (Durvalumab, Anastrozole 1mg, Letrozole 2.5mg)
Terminated
- Breast Cancer
- Hormone Receptor Positive Tumor
- Durvalumab
- +3 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
May 27, 2022
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Houston
Recruiting
- Recurrent Lung Non-Small Cell Carcinoma
- +3 more
- Durvalumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 10, 2022
Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer, Lung Cancer Trial (Ablative Radiation, Durvalumab, Etoposide)
Not yet recruiting
- Small-cell Lung Cancer
- +2 more
- Ablative Radiation
- +3 more
- (no location specified)
Mar 11, 2022
Head Neck Cancer Trial in Netherlands (PD-L1 imaging, Durvalumab)
Completed
- Head and Neck Cancer
- PD-L1 imaging
- Durvalumab
-
Amsterdam, Netherlands
- +3 more
Jan 6, 2022
Urothelial Carcinoma, Bladder Cancer Trial in Houston (Abiraterone acetate, Durvalumab, Methotrexate)
Recruiting
- Urothelial Carcinoma
- Bladder Cancer
- Abiraterone acetate
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Jun 2, 2022
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in
Not yet recruiting
- Anatomic Stage II Breast Cancer AJCC v8
- +3 more
- Biospecimen Collection
- +7 more
-
Portland, OregonSWOG
Sep 27, 2023
Breast Cancer, Triple Negative Breast Cancer, Luminal B Trial in Belgium (Paclitaxel, Epirubicin, Cyclophosphamide)
Active, not recruiting
- Breast Cancer
- +2 more
- Paclitaxel
- +3 more
-
Charleroi, Hainaut, Belgium
- +3 more
Aug 2, 2022